Sinnett Sarah E, Brenman Jay E
Neurobiology Curriculum, University of North Carolina at Chapel Hill (UNC), United States.
UNC Neuroscience Center, United States; Department of Cell Biology and Physiology, UNC, United States.
Pharmacol Ther. 2014 Jul;143(1):111-8. doi: 10.1016/j.pharmthera.2014.02.008. Epub 2014 Feb 26.
AMP-activated protein kinase (AMPK) is a promising therapeutic target for cancer, type II diabetes, and other illnesses characterized by abnormal energy utilization. During the last decade, numerous labs have published a range of methods for identifying novel AMPK modulators. The current understanding of AMPK structure and regulation, however, has propelled a paradigm shift in which many researchers now consider ADP to be an additional regulatory nucleotide of AMPK. How can the AMPK community apply this new understanding of AMPK signaling to translational research? Recent insights into AMPK structure, regulation, and holoenzyme-sensitive signaling may provide the hindsight needed to clearly evaluate the strengths and weaknesses of past AMPK drug discovery efforts. Improving future strategies for AMPK drug discovery will require pairing the current understanding of AMPK signaling with improved experimental designs.
AMP激活的蛋白激酶(AMPK)是癌症、II型糖尿病及其他以能量利用异常为特征的疾病颇具前景的治疗靶点。在过去十年间,众多实验室发表了一系列鉴定新型AMPK调节剂的方法。然而,目前对AMPK结构和调控的认识推动了一种范式转变,即许多研究人员现在认为ADP是AMPK的另一种调节核苷酸。AMPK研究领域如何将这种对AMPK信号传导的新认识应用于转化研究?最近对AMPK结构、调控和全酶敏感信号传导的见解可能提供所需的后见之明,以便清楚地评估过去AMPK药物研发工作的优缺点。改进未来AMPK药物研发策略将需要把目前对AMPK信号传导的认识与改进的实验设计相结合。